Blogs

Obesity- A Malediction In Menopause

Introduction:

Midlife, a phase marked by considerable hormonal shifts and lifestyle changes, presents unique challenges for women, particularly in terms of health and wellness. Obesity is one of the most significant concerns, affecting not only physical health but also mental well-being and general quality of life. among this essay, we will look at the intricacies of obesity among women in their midlife, including its causes, effects, and possible solutions.

 

Menopause is a seminal event produced by the decrease of ovarian follicular activity and is diagnosed retrospectively 12 months after the permanent cessation of menstruation. The average age is 46 years. At 44.69 ± 3.79 years, Indian women enter the perimenopausal stage, characterized by irregular periods. The menopausal transition period is characterized by a variety of metabolic changes, including increased body weight, total body fat, and loss of lean body mass. These changes result in central obesity, dyslipidemia, and insulin resistance in postmenopausal women.

 

Obesity has been a growing epidemic for decades. It is a well-known cause of numerous medical issues, including type 2 diabetes, hyperlipidemia, arterial hypertension, cardiovascular disease, osteoarthritis, depression, and multiple cancers, to name a few.

 

The World Health Organization defines overweight and obesity as follows:

 

Overweight is defined as having a BMI of 25 kg/m2 or higher.

 

Obesity is defined as a BMI more than or equal to 30 kg/m2.

 

Morbid obesity is defined as BMI greater than or equal to 40 kg/m2.

 

Asian population:

 

  • Overweight -BMI between 23 and 24.9 kg/m2

 

  • Obesity – BMI greater than 25 kg/m2

 

BMI is the most useful population-level metric for both sexes and all age groups of adults. Children's age must be taken into account when defining overweight and obesity.

 

Classification and Calculation of BMI



This is a graph of BMI categories based on the World Health Organization data. 



Limitations of BMI

BMI is a commonly used and helpful predictor of healthy body weight, however it has limits because it does not account for body composition. The wide range of body types, as well as the distribution of muscle, bone mass, and fat, should be considered in addition to other parameters when calculating a person's healthy body weight. BMI is also influenced by parameters including age, gender, ethnicity, muscle mass, body fat, and exercise level, among others. BMI is not completely correct because it measures extra body weight rather than excess body fat.

 

In adults:

For example, an elderly person who is deemed a healthy weight but is entirely sedentary in their everyday life may have considerable quantities of excess body fat despite not being overweight. This would be regarded unhealthy, whereas a younger person with a higher muscle composition and the same BMI would be deemed healthy. Athletes, particularly bodybuilders, who are deemed overweight because muscle weighs more than fat, may actually be at a healthy weight for their body type. Generally, according to the CDC:

  • Older persons typically have greater body fat than younger adults with the same BMI.
  • Women typically have greater body fat than men with an identical BMI.
  • Muscular people and highly trained athletes may have higher BMIs due to their increased muscle mass.

The risk of obesity skyrockets during the menopausal transition era. It is unclear whether this connection is due to diminishing ovarian hormone output or age. Preclinical data show that disrupting estradiol (E2) signaling via estrogen receptor (ER) deletion or ovariectomy (OVX) promotes fat formation, supporting the causal link with estrogen insufficiency. Current evidence from multiple large and long-running cohort studies, such as the Study of Women's Health Across the Nation (SWAN) and the Women's Health Initiative (WHI), suggests that the peri-menopausal increase in obesity, as assessed by body mass index (BMI), is caused by aging.

 

Obesity and menopausal transition

 

Menstrual abnormalities precede the final menstrual period, which is caused by a dwindling pool of ovarian follicles and variations in reproductive hormones. The Stages of Reproductive Aging Workshop +10 (STRAW+10) criteria, which are based on menstrual bleeding patterns, reflect a consensual staging scheme developed by field researchers.

 

The menopausal transition has four stages: late reproductive (−3), early menopausal (−2), late menopausal (−1), and early postmenopausal (+1). During the menopausal transition, ovarian sex steroids continue to reduce; inhibin B gradually decreases, contributing to the relaxation of negative feedback inhibition on pituitary follicle stimulating hormone (FSH) synthesis. In stage -3, FSH may be normal or occasionally raised, but it continues to climb and remains persistently elevated by early menopause.

 

Effect of obesity on vasomotor symptoms

The link between obesity and the severity of vasomotor symptoms is debatable. There are two opposing explanations that explain the relationship. The "theromoregulatory" model proposes that higher BMI and adiposity are associated with a higher prevalence of hot flashes because body adipose tissue acts as a thermal insulator, impeding heat dissipation, and the "thin hypothesis" proposes that women with excess body weight experience fewer VMS because the cytochrome P450 aromatase enzyme in fat tissue converts androgens to estrogens. increased BMI is connected with a lower incidence of hot flashes during menopause due to increased levels of estrone, which may lessen hot flash frequency.

 

Effect of menopause on obesity

Obesity is associated with a decrease in circulating estrogen (i.e., estradiol) levels during menopause. Among premenopausal women, estrogen levels are inversely related to obesity. E2 influences many energy homeostasis pathways, including central nervous system (CNS) control of food intake and energy expenditure, regulation of lipid storage and metabolism in adipose tissue, and insulin sensitivity.  Experiments with laboratory animals (e.g., estrogen receptor knockout and knock-in models, as well as ovariectomy with and without hormone supplementation) have shown that, in the absence of estrogens, a general mechanism for fat gain operates by lowering metabolic rate at rest, decreasing spontaneous physical activity, and increasing caloric intake.

 

Not only does the menopause facilitate weight gain, it modifies the pattern of fat distribution. Ovarian estrogens promote peripheral fat storage in the gluteal and femoral subcutaneous region, whereas androgens (mainly bioavailable testosterone) stimulate visceral abdominal fat accumulation. This is irrespective of age, race, total fat mass, and other cardiovascular risk factors and changes following the menopause.

 

Menopause and cardio-metabolic risk

Abdominal fat is recognized as a metabolically active endocrine organ that secretes numerous adipokines and substances linked to insulin resistance, type 2 diabetes, and metabolic syndrome. Alterations in adipokine release from visceral fat initiate inflammation and play a role in insulin resistance, leading to elevated levels of circulating insulin .

 

Because most VAT is drained by the portal vein, the hyperlipolytic state of large (hypertrophic) adipocytes associated with visceral obesity exposes the liver to high concentrations of free fatty acids and glycerol, leading to several impairments in liver metabolism, such as reduced hepatic extraction of insulin (exacerbating hyperinsulinemia) and increased production of triglyceride-rich lipoproteins, as well as increased production of hepatic glucose, which explains the link between visceral obesity and glucose intolerance and type 2 diabetes .

Obesity and osteoporosis:

The notion that obesity has a protective effect against fractures has influenced clinical practice, with BMI being a component of the Fracture Risk Assessment Tool (FRAX). Research has shown a positive correlation between bone mineral density (BMD) and BMI, as well as a lower incidence of hip fractures in adults with obesity . A systematic review and meta-analysis of 121 studies found higher BMD in the lumbar spine, total hip, femoral neck, and radius in men and women with obesity compared to their counterparts with normal weight.

 

Menopausal obesity and risk of cancer:

Obesity after menopause, particularly visceral adiposity, increases the risk of developing breast cancer. Many studies have revealed that postmenopausal women who accumulate abdominal fat tissue are more likely to develop breast cancer. The risk of postmenopausal breast cancer rises by 11% for every 5 kilograms added as an adult. Overweight or obese women have a 1.5-2 times increased risk of postmenopausal estrogen receptor positive (ERþ) and progesterone receptor-positive breast cancer, with an increase of 70% for ER þ breast cancer.

 

Management of menopause and related obesity:

Obesity management consists of lifestyle changes, as well as pharmaceutical and nonpharmacological interventions. Non-pharmacological treatments for managing grade I obesity include a low-calorie diet and increased physical exercise. Pharmacological therapy is indicated for patients who are unable to meet their weight loss objectives using these methods. Indications for grade II and grade III obesity include personalized pharmacological and surgical recommendations.

 

Lifestyle changes and exercise:

Lifestyle changes, such as regular physical activity and dietary management, have a positive effect and prevention of metabolic diseases. Intensive lifestyle changes leading to weight loss have been shown to reduce various menopausal symptoms.

Recommended activities for menopausal women

Step I: Aging makes the body less flexible. Start with warm‑up exercises such as full body stretches, walking for 10 min on the treadmill, suryanamaskar, etc. Warming up helps to prepare the body for exercise by gradually increasing physical activity, joint mobility, and stretching.

Step II : Aerobic exercises help to burn calories and provide cardiometabolic benefits to older women. Aerobic exercise can be initiated by walking for a short duration at a comfortable pace.

Step III : Short bouts of resistance exercise and strength training can also be incorporated using resistance bands, weight resistance, or utilizing one’s own body weight. It is recommended that these exercises can be incorporated on every alternate day focusing on the abdomen, arms, legs, shoulders, and hips.

Step IV: Practicing yoga and stretches help to maintain flexibility in older age women to perform daily chores. These light intensity exercise do not spike the vasomotor symptoms and help to ease the psychological symptoms.

Step V : Balance exercises help in postural and gait control to prevent falls in menopausal women. Practices such as tai chi, pilates, and some functional exercises Can help to maintain balance

Step VI :The exercise session should conclude with cooling down exercises such as walking a few minutes and muscle relaxing postures and stretches which will ease the pain. Regular exercise has both short‑term and long‑term benefits in menopausal women .

Strength training: Due to the strong influence of aging and the menopause on body composition, including the loss of lean mass, exercise designed to improve and maintain muscle mass is critical. In this regard, strength training has been the focus of some studies examining how exercise may mitigate metabolic dysfunction following the menopause. A study investigating the association of resistance training exercise frequency and volume with changes in body composition among postmenopausal women found that resistance training was successful in preventing weight gain and deleterious changes in body composition.

High-intensity interval training: The metabolic benefits of high intensity interval training (HIIT) are well established. A recent meta-analysis concluded that HIIT is a time-efficient, feasible, and effective intervention to modify body composition by reducing abdominal and visceral fat mass . Lean mass increases the basal metabolic rate and total energy expenditure, so the combination of HIIT and resistance training may be an equally beneficial exercise modality for postmenopausal women .



v  Dietary strategies for weight loss:

        1.Based on amount of food intake :


Low calorie diet

Consumption of 1,000–1,500 calories and deficit of 500–750 calories per day. Recommended as the initial strategy

Very low calorie diet

Consumption of 600–900 calories per day. Can be maintained for a relatively short time period of time (2 weeks to 3 months), followed by a gradual switch to a low-calorie diet. Considered for severe obesity, sarcopenic obesity, obesity associated with type 2 diabetes, hypertriglyceridemia, and hypertension

Meal replacements

Useful for controlling calories without placing much effort on calorie calculation or meal planning May include either total or partial meal replacements (one or two meals a day)

.2 .Types of food eaten:

Low fat diet

Consumption of fat as < 15%–20% of daily calories, especially saturated fatty acids as < 7%–10%.Mostly plant-based meals

Low carbohydrate diet

Consumption of carbohydrates as < 45% of daily calories or < 130 mg/day. Recommended as a dietary strategy for type 2 diabetes. Might be useful for initial weight loss, but long-term results are similar to following a low-fat diet.

Ketogenic diet

Consumption of carbohydrates as < 10% of daily calories or < 50 mg/day. May decrease appetite, but long-term safety is unknown

High protein diet

Increase protein intake to 30% of total daily calories or 1–1.2 g/kg of ideal body weight. Useful in maintaining weight loss and increasing satiety. High-protein diets from animal sources should be handled with caution for people with risk of chronic kidney disease.

Mediterranean diet

Consists of high consumption of fruits and vegetables, poultry, fish, dairy products, and monounsaturated fats, with little to no consumption of red meat. Helpful in improving cardiometabolic parameters and cognitive function.


Intermittent fasting :Intermittent fasting involves regular periods with no or very limited calorie intake. The three most widely used regimens are alternate-day fasting, 5:2 intermittent fasting (fasting or consuming 900–1,000 calories for 2 days each week), and daily timerestricted feeding (fasting for 16–18 hours a day). The benefits of intermittent fasting come not only from reduction in calorie intake, but also from its effects on metabolic switching to reverse insulin resistance, strengthen the immune system, and enhance physical and cognitive function.

 

Behavioral therapy: Behavioral therapy is a set of strategies, which includes goal setting, problem‑solving, emotional eating, stimulus control, and relapse prevention. These strategies aim to better patient’s adherence to dietary and exercise regimens.

 

Pharmacological treatment:

·   Menopausal Hormone Therapy (MHT): It is a recommended treatment option for women experiencing menopausal symptoms, particularly vasomotor symptoms (VMS).  MHT should be individualized based on women's needs, symptoms, and clinical conditions. It is essential to consider the best type, route, dose, and duration of MHT, taking into account factors such as efficacy, tolerability, adherence, and any other relevant aspects . This individualized approach can help ensure that women receive the most appropriate and effective treatment for their menopausal symptoms.  When prescribing (MHT), it is important to consider obesity due to the endocrine nature of adipose tissue, which produces estrogens and is linked to conditions like the metabolic syndrome.

While MHT has demonstrated benefits in reducing cardiovascular risk, osteoporosis, bone fractures, improving genitourinary syndrome of menopause, and enhancing quality of life, it should not be prescribed solely for preventive purposes .  

·     Anti-Obesity Drugs: In Asian Indians, pharmacotherapy should be initiated along with lifestyle modifications in individuals with a BMI >27 kg/m2 or in individuals with a BMI >25 kg/m2 with at least one associated comorbid medical condition such as hypertension, dyslipidemia, type 2 diabetes (T2DM), and obstructive sleep apnea. A higher cutoff of BMI >30 kg/m2 or >27 kg/m2 with comorbidities are endorsed by western guidelines .

Pharmacotherapy presently approved includes orlistat, phentermine and topiramate comibination, Liraglutide and semaglutide.

 

Bariatric (metabolic) surgeryIt is a complementary method of treating obesity in the case of ineffective behavioral treatment and pharmacotherapy. Among the many available surgical methods, such as Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch, sleeve gastrectomy, or laparoscopic adjustable gastric banding (LAGB) seem to be associated with high efficacy and a positive result, which largely depends on the experience of the surgeon performing the procedure. On the other hand, maintaining the achieved effect of surgical treatment depends primarily on the patient and the continuation of non-pharmacological and pharmacological methods used by them. According to current guidelines (Endocrine society 2016), indications for bariatric surgery include:

— class 3 obesity (BMI ≥ 40 kg/m2);

— class 2 obesity (BMI 35–39.9 kg/m2), with ≥ 1 obesity related complication

 

Conclusions:

Menopausal transition is characterized by unfavorable changes in body composition characterized by increase in fat mass and decrease in lean muscle mass. Obesity is a well-known risk factor for CVS disease, metabolic syndrome, and several malignancies. These changes are primarily due to aging or hormonal changes are still a matter of debate. In women with obesity, combined oral MHT should not be the first choice because the evidence shows an increased risk of thromboembolic disease; although the absolute risk, especially in those under 60 years of age, is low. The use of estrogen-only or combined transdermal MHT does not increase the risk of thrombotic events in women with obesity. MHT has been shown to reverse the menopausal transition associated increase in abdominal and visceral adiposity Obesity in women during midlife is a complex and multifaceted issue with significant implications for health and well-being. By understanding the underlying causes, recognizing the impacts and implementing comprehensive strategies for prevention and treatment, we can work towards reducing the prevalence of obesity and improving the overall health outcomes and quality of life for midlife women. Empowering women to make informed choices and providing the necessary support systems are critical steps towards this goal.

 

References:

1.      Ahuja M. Age of menopause and determinants of menopause age: A PAN India survey by IMS. J Midlife Health. 2016 Jul-Sep;7(3):126-131.

2.      El Khoudary SR, Greendale G, Crawford SL et al., The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019 Oct;26(10):1213-1227.

3.      Farahmand M, Ramezani Tehrani F, Rahmati M, Azizi F. Anthropometric indices and age at natural menopause: a 15-year follow-up population-based study. Int J Endocrinol Metabol 2021 Aug 5;19(4).

4.      Harlow SD, Gass M, Hall JE, et al.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause.2012;19(4):387-395.

5.      Nanette et al, The menopausal transition: Signs, symptoms and management options, The journal of clinical endocrinology and metabolism,volume 106 ,Issue 1,January 2021,pages 1-15

6.      Paramsothy P, Harlow SD, Nan B, et al.  Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause.2017;24(2):142-149.

7.      Li Y, Zhao D, Wang M, Sun J, Liu J, Qi Y, et al. Association between body mass index, waist circumference, and age at natural menopause: a population-based cohort study in Chinese women. Women Health 2021;61(9):902e13.

8.      Palacios S, Chedraui P, Sánchez-Borrego R, Coronado P, Nappi RE. Obesity and menopause. Gynecol Endocrinol. 2024 Dec;40(1):2312885.

9.      Van Pelt RE, Gavin KM, Kohrt WM. Regulation of body composition and bioenergetics by estrogens. Endocrinol Metab Clin North Am. 2015;44(3):663–676.

10.  Gao B, Huang Q, Lin YS, et al. Dose-dependent effect of estrogen suppresses the osteo-adipogenic transdifferentiation of osteoblasts via canonical wnt signaling pathway. PLoS One. 2014;9(6):e99137.

11.  Chen J, Zhu L, Yao X, et al. The association between abdominal obesity and femoral neck bone mineral density in older adults. J Orthop Surg Res. 2023;18(1):171.

12.  Zuo Q, Band S, Kesavadas M, Madak Erdogan Z. Obesity and postmenopausal hormone receptor-positive breast cancer: epidemiology and mechanisms. Endocrine Society Endocrinology (United States) 2021;162.

13.  Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017;376:254‑66.

14.  Maillard, F.; Pereira, B.; Boisseau, N. Effect of High-Intensity Interval Training on Total, Abdominal and Visceral Fat Mass: A Meta-Analysis. Sport Med. 2018, 48, 269–288.

15.  Grossman, J.; Arigo, D. Meaningful weight loss in obese postmenopausal women: A pilot study of high-intensity interval training and wearable technology. Menopause 2018, 25, 465–470.

16.  Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11): 3975–4011.

17.  Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.

18.  Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults:A clinical practice guideline. CMAJ. 2020;19:E875–91.

19.  Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330– 342.

20.  Gadde KMD, Allison DBP, Ryan DHMD, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.

21.  Timothy Garvey W, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.

22.   Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22.

23.  Zhong P, Zeng H, Huang M, Fu W, Chen Z. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis. Endocrine. 2022;75(3):718–724.

24.  Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023 Mar 20;58:101882.




Book Appointment